Starpharma Holdings Limited Stock Performance
| SPHRF Stock | USD 0.25 0.00 0.00% |
Starpharma Holdings holds a performance score of 11 on a scale of zero to a hundred. The entity has a beta of 1.26, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Starpharma Holdings will likely underperform. Use Starpharma Holdings information ratio, as well as the relationship between the skewness and day typical price , to analyze future returns on Starpharma Holdings.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Starpharma Holdings Limited are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Starpharma Holdings reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 60.5 M | |
| Total Cashflows From Investing Activities | -836 K |
Starpharma |
Starpharma Holdings Relative Risk vs. Return Landscape
If you would invest 10.00 in Starpharma Holdings Limited on September 28, 2025 and sell it today you would earn a total of 15.00 from holding Starpharma Holdings Limited or generate 150.0% return on investment over 90 days. Starpharma Holdings Limited is currently producing 2.2564% returns and takes up 16.1149% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Starpharma, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Starpharma Holdings Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Starpharma Holdings' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Starpharma Holdings Limited, and traders can use it to determine the average amount a Starpharma Holdings' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.14
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | SPHRF | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Starpharma Holdings is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Starpharma Holdings by adding it to a well-diversified portfolio.
Starpharma Holdings Fundamentals Growth
Starpharma OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Starpharma Holdings, and Starpharma Holdings fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Starpharma OTC Stock performance.
| Return On Equity | -0.29 | |||
| Return On Asset | -0.14 | |||
| Operating Margin | (3.13) % | |||
| Current Valuation | 123.62 M | |||
| Shares Outstanding | 408.92 M | |||
| Price To Earning | 46.82 X | |||
| Price To Book | 4.36 X | |||
| Price To Sales | 28.59 X | |||
| Revenue | 4.68 M | |||
| EBITDA | (16.63 M) | |||
| Cash And Equivalents | 49.92 M | |||
| Cash Per Share | 0.12 X | |||
| Total Debt | 4 M | |||
| Debt To Equity | 0.17 % | |||
| Book Value Per Share | 0.12 X | |||
| Cash Flow From Operations | (13.16 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 66.17 M | |||
| Retained Earnings | (154 M) | |||
| Current Asset | 50 M | |||
| Current Liabilities | 10 M | |||
About Starpharma Holdings Performance
By analyzing Starpharma Holdings' fundamental ratios, stakeholders can gain valuable insights into Starpharma Holdings' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Starpharma Holdings has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Starpharma Holdings has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company was founded in 1996 and is headquartered in Abbotsford, Australia. Starpharma Holdings operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 50 people.Things to note about Starpharma Holdings performance evaluation
Checking the ongoing alerts about Starpharma Holdings for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Starpharma Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Starpharma Holdings is way too risky over 90 days horizon | |
| Starpharma Holdings has some characteristics of a very speculative penny stock | |
| Starpharma Holdings appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 4.68 M. Net Loss for the year was (16.15 M) with loss before overhead, payroll, taxes, and interest of (9.29 M). | |
| Starpharma Holdings Limited has accumulated about 49.92 M in cash with (13.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12. |
- Analyzing Starpharma Holdings' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Starpharma Holdings' stock is overvalued or undervalued compared to its peers.
- Examining Starpharma Holdings' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Starpharma Holdings' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Starpharma Holdings' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Starpharma Holdings' otc stock. These opinions can provide insight into Starpharma Holdings' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Starpharma OTC Stock analysis
When running Starpharma Holdings' price analysis, check to measure Starpharma Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Starpharma Holdings is operating at the current time. Most of Starpharma Holdings' value examination focuses on studying past and present price action to predict the probability of Starpharma Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Starpharma Holdings' price. Additionally, you may evaluate how the addition of Starpharma Holdings to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |